Literature DB >> 9849054

[Multi-organ involvement in recurrent Moschcowitz disease. Splenectomy as ultima ratio in a therapeutic dilemma?].

A R Jakob1, E Hiller.   

Abstract

BACKGROUND: The symptoms primarily described in Morbus Moschcowitz included thrombocytopenic purpura and hemolytic anemia. In addition it presents with a variety of clinical manifestations depending on the organs involved (i.e. neurological, renal, gastrointestinal, cardiac involvement). It is a rare disease and the pathogenesis still remains unclear. The efficacy of derived therapeutical concepts can hardly be assessed in controlled trials.
CONCLUSION: Currently the main option seems to be plasma therapy. In non-responders surgical procedures (splenectomy) may be of benefit to the patient.

Entities:  

Mesh:

Year:  1998        PMID: 9849054     DOI: 10.1007/bf03042678

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  19 in total

Review 1.  The pathophysiology and management of thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; G Remuzzi
Journal:  Eur J Haematol       Date:  1996-04       Impact factor: 2.997

Review 2.  Antiplatelet therapy in thrombotic thrombocytopenic purpura.

Authors:  G J del Zoppo
Journal:  Semin Hematol       Date:  1987-04       Impact factor: 3.851

3.  High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients.

Authors:  M Rose; A Eldor
Journal:  Am J Med       Date:  1987-09       Impact factor: 4.965

4.  Treatment of thrombotic thrombocytopenic purpura with plasma.

Authors:  J J Byrnes; M Khurana
Journal:  N Engl J Med       Date:  1977-12-22       Impact factor: 91.245

5.  Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.

Authors:  J L Moake; C K Rudy; J H Troll; M J Weinstein; N M Colannino; J Azocar; R H Seder; S L Hong; D Deykin
Journal:  N Engl J Med       Date:  1982-12-02       Impact factor: 91.245

6.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

7.  Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  M A Crowther; N Heddle; C P Hayward; T Warkentin; J G Kelton
Journal:  Ann Intern Med       Date:  1996-08-15       Impact factor: 25.391

Review 8.  The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura.

Authors:  G A Veltman; A Brand; O C Leeksma; G J ten Bosch; J H van Krieken; E Briët
Journal:  Ann Hematol       Date:  1995-05       Impact factor: 3.673

Review 9.  Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy.

Authors:  L A Hochstetler; M J Flanigan; D J Lager
Journal:  Am J Kidney Dis       Date:  1994-03       Impact factor: 8.860

10.  Thrombotic thrombocytopenic purpura: indications for and results of splenectomy.

Authors:  G A Winslow; E W Nelson
Journal:  Am J Surg       Date:  1995-12       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.